WO1998051704A1 - PEPTIDES FAVORISANT L'ACTIVATION DE TGF-β LATENT ET PROCEDE DE SELECTION DE REGULATEURS A ACTIVITE DE TGF-$g(b) - Google Patents

PEPTIDES FAVORISANT L'ACTIVATION DE TGF-β LATENT ET PROCEDE DE SELECTION DE REGULATEURS A ACTIVITE DE TGF-$g(b) Download PDF

Info

Publication number
WO1998051704A1
WO1998051704A1 PCT/JP1998/002089 JP9802089W WO9851704A1 WO 1998051704 A1 WO1998051704 A1 WO 1998051704A1 JP 9802089 W JP9802089 W JP 9802089W WO 9851704 A1 WO9851704 A1 WO 9851704A1
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
promoting
activity
screening
latent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1998/002089
Other languages
English (en)
French (fr)
Inventor
Motoo Yamasaki
Kenji Shibata
Yasufumi Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to EP19980919563 priority Critical patent/EP0922710A4/en
Priority to CA002259956A priority patent/CA2259956A1/en
Priority to AU72360/98A priority patent/AU736207B2/en
Priority to JP54904498A priority patent/JP4104671B2/ja
Publication of WO1998051704A1 publication Critical patent/WO1998051704A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP1998/002089 1997-05-12 1998-05-12 PEPTIDES FAVORISANT L'ACTIVATION DE TGF-β LATENT ET PROCEDE DE SELECTION DE REGULATEURS A ACTIVITE DE TGF-$g(b) Ceased WO1998051704A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP19980919563 EP0922710A4 (en) 1997-05-12 1998-05-12 PEPTIDES SUPPORTING THE ACTIVATION OF LATENT TGF-BETA AND A METHOD FOR IDENTIFYING REGULATORS OF TGF-BETA ACTIVITY.
CA002259956A CA2259956A1 (en) 1997-05-12 1998-05-12 Peptides promoting the activation of latent tgf-.beta. and method for screening tgf-.beta. activity regulators
AU72360/98A AU736207B2 (en) 1997-05-12 1998-05-12 Peptides which promote activation of latent TGF-beta and method of screening TGF-beta activity-regulating compounds
JP54904498A JP4104671B2 (ja) 1997-05-12 1998-05-12 潜在型ＴＧＦ―βの活性化を促進するペプチドおよびＴＧＦ―β活性調節化合物のスクリーニング方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9/120683 1997-05-12
JP12068397 1997-05-12

Publications (1)

Publication Number Publication Date
WO1998051704A1 true WO1998051704A1 (fr) 1998-11-19

Family

ID=14792374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/002089 Ceased WO1998051704A1 (fr) 1997-05-12 1998-05-12 PEPTIDES FAVORISANT L'ACTIVATION DE TGF-β LATENT ET PROCEDE DE SELECTION DE REGULATEURS A ACTIVITE DE TGF-$g(b)

Country Status (8)

Country Link
US (1) US20030027218A1 (ja)
EP (1) EP0922710A4 (ja)
JP (1) JP4104671B2 (ja)
KR (1) KR20000023669A (ja)
CN (1) CN1226898A (ja)
AU (1) AU736207B2 (ja)
CA (1) CA2259956A1 (ja)
WO (1) WO1998051704A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105144A1 (ja) * 2004-04-30 2005-11-10 Kyowa Hakko Kogyo Co., Ltd. 潜在型ＴＧＦ－βの活性化抑制剤
JP2022535102A (ja) * 2019-06-05 2022-08-04 アイオー バイオテック エーピーエス Ｔｇｆ－ベータワクチン

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756215B1 (en) * 2000-10-20 2004-06-29 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Functionalized TGF-β fusion proteins
JP6975896B2 (ja) 2017-02-03 2021-12-01 パナソニックＩｐマネジメント株式会社 撮像装置の制御方法及び撮像装置
KR102069184B1 (ko) * 2019-06-28 2020-01-22 (주)미래씨티 신경줄기세포 추출물유래 bmp신호전달경로 억제 펩타이드 및 상기 펩타이드를 유효성분으로 포함하는 발모촉진 또는 탈모방지 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6014171A (ja) * 1983-07-05 1985-01-24 Toyo Jozo Co Ltd トランスホ−ミンググロスファクタ−の定量方法
JPH08510443A (ja) * 1993-01-26 1996-11-05 セルトリックス ファーマシューティカルズ，インコーポレイテッド 生物学的に活性なＴＧＦ−β１およびＴＧＦ−β２ペプチド

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6014171A (ja) * 1983-07-05 1985-01-24 Toyo Jozo Co Ltd トランスホ−ミンググロスファクタ−の定量方法
JPH08510443A (ja) * 1993-01-26 1996-11-05 セルトリックス ファーマシューティカルズ，インコーポレイテッド 生物学的に活性なＴＧＦ−β１およびＴＧＦ−β２ペプチド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SATO Y., ET AL.: "THE MECHANISM FOR THE ACTIVATION OF LATENT TGF-BETA DURING CO- CULTURE OF ENDOTHELIAL CELLS AND SMOOTH MUSCLE CELLS: CELL-TYPE SPECIFIC TARGETING OF LATENT TGF-BETA TO SMOOTH MUSCLE CELLS.", THE JOURNAL OF CELL BIOLOGY : JCB, THE ROCKEFELLER UNIVERSITY PRESS, US, vol. 123., no. 05., 1 December 1993 (1993-12-01), US, pages 1249 - 1254., XP002914417, ISSN: 0021-9525, DOI: 10.1083/jcb.123.5.1249 *
See also references of EP0922710A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105144A1 (ja) * 2004-04-30 2005-11-10 Kyowa Hakko Kogyo Co., Ltd. 潜在型ＴＧＦ－βの活性化抑制剤
JP2022535102A (ja) * 2019-06-05 2022-08-04 アイオー バイオテック エーピーエス Ｔｇｆ－ベータワクチン
JP7758573B2 (ja) 2019-06-05 2025-10-22 アイオー バイオテック エーピーエス Ｔｇｆ－ベータワクチン

Also Published As

Publication number Publication date
AU7236098A (en) 1998-12-08
CN1226898A (zh) 1999-08-25
EP0922710A1 (en) 1999-06-16
CA2259956A1 (en) 1998-11-19
JP4104671B2 (ja) 2008-06-18
EP0922710A4 (en) 2002-10-25
US20030027218A1 (en) 2003-02-06
KR20000023669A (ko) 2000-04-25
AU736207B2 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
AU2002211317A1 (en) Methods and compositions for directed microwave chemistry
EP0933365A3 (en) Growth hormone secretagogues
EP1507005A3 (en) Antisense modulation of BCL-X expression
AU2560599A (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
CA2294320A1 (en) Electrodepositable coating compositions and their use in a method of cationic electrodeposition
AU8567898A (en) Electrochemical methods for recovery of ascorbic acid
BR0114630A (pt) Secretagogos de hormÈnio do crescimento
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
AU4988999A (en) Compositions and methods of treating abnormal cell proliferation
AU5812400A (en) Carrier-drug conjugate
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
WO1997044356A3 (en) Ret ligand (retl) for stimulating neural and renal growth
WO1998000532A3 (en) Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
MXPA02005510A (es) Compuestos, composiciones y metodos para estimular el crecimiento y alargamiento neuronal.
GB9907813D0 (en) Synthesis
BR9811076A (pt) Composição para revestimento, processo para revestir um substrato, e, substrato revestido
ATE266030T1 (de) 1,4,7,10-tetraazabicyclo(8.2.2)tetradecan-2-on, verfahren zu ihrer herstellung und ihrer verwendung für die herstellung von tetraazamacrocyclen
ZA9810915B (en) Optimization of cells for endogenous gene activation.
ZA988674B (en) 21-Hydroy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids
AU1292899A (en) Pyrimidine derivatives for labeled binding partners
MY138257A (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
WO1998051704A1 (fr) PEPTIDES FAVORISANT L'ACTIVATION DE TGF-β LATENT ET PROCEDE DE SELECTION DE REGULATEURS A ACTIVITE DE TGF-$g(b)
Shiosaki et al. Development of CCK-tetrapeptide analogs as potent and selective CCK-A receptor agonists
EP0292101A3 (en) Process for the preparation of 3'-azido-3'-deoxythymidine and intermediates
WO2004003152A3 (en) Sos1 inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98800622.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA CN CZ HU IL JP KR MX NO NZ PL RO SG SI SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2259956

Country of ref document: CA

Ref document number: 2259956

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09214592

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1019997000124

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 72360/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998919563

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1998919563

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997000124

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 72360/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1019997000124

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998919563

Country of ref document: EP